| |
F2P Company Portfolio
F2P is currently working on a number of projects:
- Glythera is a young biopharmaceutical company
applying a broad range of proprietary platforms to improve the
product homogeneity and storage and PK profiles of biologics including
full length recombinant proteins and peptides. Formed in 2008
with backing from the IP Group and being based on technology arising
from the University of Bath (Drs Andy Watts and Amanda MacKenzie)
the company has already secured one major collaboration with a
large European Biotech.
Applications include improvements on existing Pegylated proteins
such as PEG-interferons and PEG-G-CSF’s as well as to antibody
and antibody fragments. Simon Youlton works on a retained part
time basis providing Business Development Management skills and
reporting directly to the Board. (see www.Glythera.com)
- OncoBiomarkers is a company in gestation based
on proprietary biomarkers for oncology and the delivery of accredited
tests to the clinical community as well as working with pharmaceutical
companies to identify and qualify biomarkers used as potential
companion diagnostics.
The company is based on assets to be spun out of the University
of Liverpool, including access to a large annotated Biobank of
cancer biopsies with patient histories. Simon is responsible for
bringing together a viable business plan for funding and networking
with University research groups to leverage the best value in
their IP assets and formulate a fast-track development program.
|
